Korean Market
EXCH
Daewoong Pharma
★

Corporate Governance Report: Enhancement of Governance Structure with New Audit and Nomination Committees, Improved Dividend Predictability

 
EXCH
Daewoong Pharma
★

Daewoong Pharma Submits NDA for Diabetes Combo 'Enblozem' Based on Positive Phase 3 Results, Boosting New Product Launch Prospects

 
EXCH
Daewoong Pharma
★★

Daewoong Pharma Receives Mexico Marketing Approval for Diabetes Drug Envlo, Expanding into Latin America for Overseas Sales Growth

 
EXCH
Daewoong Pharma
★★

Daewoong Pharma Enters Technology Introduction Contract for Semaglutide Long-Acting Injectable (Conditional, Amount Undisclosed)

 
EXCH
Daewoong Pharma
★★

Completion of Licensor Succession for mRNA-based ERA Platform Technology Transfer Agreement (Total USD 239M)

 
PERI
Daewoong Pharma
★

Daewoong Pharmaceutical 2026 Q1: Revenue Growth Continues, Operating Profit Declines, New Technology Acquisition and Pipeline Strength

 
EXCH
Daewoong Pharma
★★

Technology Introduction Contract Signed for INV-008 (15-PGDH Inhibitor)

 
EXCH
Daewoong Pharma
★★

Q1 2026 Preliminary Results: Operating Profit Down, Net Income Up

 
EXCH
Daewoong Pharma
★★

Assumption of Licensor Position in mRNA-based ERA Technology (Contract with HanAll BioPharma)

 
EXCH
Daewoong Pharma
★★★★

Fexuclue Gets Additional Indication for H. pylori Eradication